WO2003022281A1 - Verbesserung der lokalen verträglichkeit bei intravenöser verabriechung von 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluormethyl-benzoylguanidin - Google Patents
Verbesserung der lokalen verträglichkeit bei intravenöser verabriechung von 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluormethyl-benzoylguanidin Download PDFInfo
- Publication number
- WO2003022281A1 WO2003022281A1 PCT/EP2002/009768 EP0209768W WO03022281A1 WO 2003022281 A1 WO2003022281 A1 WO 2003022281A1 EP 0209768 W EP0209768 W EP 0209768W WO 03022281 A1 WO03022281 A1 WO 03022281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- pyrrolylcarbonyl
- piperazinyl
- acid
- benzoylguanidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the invention relates to formulations of 4- (4- (2-pyrrolylcarbonyl) -1-piperazinyl) -3- trifluoromethyl-benzoylguanidine hydrochloride which have local compatibility, i.e. improve the tolerance at the injection or infusion site of 4- (4- (2-pyrrolylcarbonyl) -1-piperazinyl) -3-trifluoromethyl-benzoylguanidine when used intravenously.
- the formulations according to the invention include complexing the active ingredient with cyclodextrins, especially with hydroxypropyl- ⁇ -cyclodextrin, complexing the active ingredient with cyclodextrins and hydroxy acids, enveloping the active ingredient in polymer balls, e.g. in poloxamer, polyvinylpyrrolidone or polysorbate, and the incorporation of the active ingredient in mixed micelles consisting of a phospholipid and a bile salt.
- Alkylaryl unsubstituted or substituted one or more times in the aryl and / or alkyl partial structure with a branched or unbranched C 1 -C 4 -
- Alkyl groups a branched or unbranched C 1 -C 4 alkoxy group, an NH 2 group or a primary or secondary amino group of a trifluoromethyl group, a cyano or nitro group or halogen,
- Such compounds can be used as active ingredients in medicinal products or can be used as intermediates for the production of such active ingredients.
- the compounds according to the invention act against arrhythmias which occur, for example, in hypoxia. They can also be used for diseases related to ischemia (examples: cardiaie, cerebrale, gastrointestinal - such as mensenteriale throbose / embolie -, pulmonary, renal ischemia, ischemia of the liver, Ischemia of the skeletal muscles).
- Corresponding diseases are, for example, coronary heart disease, heart attack, angina pectoris, stable angina pectoris, ventricular arrhythmias, subventricular arrhythmias, heart failure - furthermore to support bypass operations, to support open heart operations, to support operations that interrupt the blood supply of the heart and to support heart transplants - embolism in the pulmonary circulation, acute or chronic kidney failure, chronic renal failure, cerebral infarction, reperfusion damage when the brain is re-supplied with blood after dissolution of vascular occlusions and acute and chronic circulatory disorders in the brain.
- the compounds mentioned are also useful in combination with thrombolytic agents such as t-PA, streptokinase and urokinase.
- the compounds of the invention act inter alia. in such a case cardioprotective.
- the ischemia area of application also includes the prevention of damage to grafts (e.g. as protection of the graft - such as the liver, kidney, heart or lungs - before, during and after implantation and during the storage of the grafts) May be associated with transplants.
- the compounds are also protective drugs when performing angioplasty surgery on the heart and peripheral vessels.
- Cellular sodium-proton exchange is increased in essential hypertension and diabetic nephropathy.
- the compounds according to the invention are therefore suitable as inhibitors of this exchange for the preventive treatment of these diseases.
- the compounds according to the invention are furthermore distinguished by a strongly inhibiting effect on the proliferation of cells.
- the compounds are therefore of interest as medicaments for diseases in which cell proliferation plays a primary or secondary role and can be used as a remedy for cancer diseases, benign tumors, or for example prostate hypertrophy, atherosclerosis, organ hypertrophies and hyperplasias, fibrotic diseases and late diabetic complications , Furthermore, compounds of this type are known to have a favorable influence on the blood levels of the serum lipoproteins.
- the incompatibilities often have completely different causes.
- it can be the physico-chemical properties of the preparation, such as pH value, buffer capacity, tonicity, which deviate more or less strongly from the physiological conditions at the injection / infusion site and lead to undesirable reactions there, especially when the application is prolonged.
- the active ingredient per se can interact undesirably with the morphological structures at the injection / infusion site.
- the principle of these measures is to reduce the current concentration of the formulation or the active ingredient.
- the object of the invention is to formulate the sodium proton exchange inhibitor 4- (4- (2-pyrrolylcarbonyl) -1-piperazinyl) -3-trifluoromethyl-benzoylguanidine in such a way that no local incompatibility immediately after and after intravenous administration occurs as it was observed with the administration of aqueous, isotonic solutions on animals without measures to improve tolerance.
- the tolerance improvement should not be achieved by any of the usual measures such as increasing the application volume or extending the duration of the infusion. Improving local tolerance is particularly important for bolus injection in emergencies.
- the quantitative data used below always refer to the free base, ie the quantity indicated corresponds to the theoretical amount of free base, while in fact a correspondingly larger amount of hemihydrate was weighed in.
- Glucose was taken as isotonans in all cases.
- the isotonicity of the solutions was checked in each case with lowering of the freezing point
- the solution to be tested was mixed with human citrate blood in a ratio of 1: 1 and kept at 37 ° C. during the incubation period.
- the intravenous dosage form contains the active ingredient in doses of 150 mg / person - 600 mg / person.
- the application volumes are in the range from 15 ml to 250 ml.
- the active substance concentrations are therefore between 0.6 mg / ml and 40 mg / ml.
- a concentration of 0.75 mg / ml was found to be incompatible in a rat study (30 minutes infusion into the tail vein).
- An improvement in compatibility according to the invention can be achieved by adding cyclodextrins, in particular ⁇ -cyclodextrins.
- cyclodextrins in particular ⁇ -cyclodextrins.
- the appropriate ratio of HPßCD to active ingredient was determined based on the local tolerance in the dog.
- a weight ratio of 10: 1 (HPßCD: active ingredient) proved to be suitable both with a bolus (active ingredient concentration 10 mg / ml) and with an infusion (active ingredient concentration between 1.5 mg / ml and 3 mg / ml). This corresponds to a molar ratio of approximately 3: 1.
- Further investigations showed that a quantitative ratio of HPßCD to active ingredient of 6.67: 1 at an active ingredient concentration of 9 mg / ml is not hemolytic.
- Another embodiment of the invention relates to the improvement in tolerance by complexing the active ingredient with cyclodextrins and hydroxy acids.
- the amount of cyclodextrin required to improve the tolerance of 4- (4- (2-pyrrolylcarbonyl) -1-piperazinyl) -3-trifluoromethyl-benzoylguanidine can be formed by the formation of a ternary complex consisting of 4- (4- (2-pyrrolylcarbonyl) - 1- piperazinyl) -3-trifluoromethyl-benzoylguanidine, the respective cyclodextrin and hydroxy acid can be reduced.
- suitable hydroxy acids are malic acid, acetic acid, lactic acid, tartaric acid and citric acid. Citric acid is preferably used.
- Another object of the invention is to improve the tolerance by enveloping the active substance in polymer balls, for example in poloxamer, polyvinylpyrrolidone or polysorbate.
- PVP 17 PF polyvinylpyrrolidone 17 PF
- 4- (4- (2-pyrrolylcarbonyl) -1-piperazinyl) -3-trifluoromethyl-benzoylguanidine and 100 mg / ml are added to an aqueous, isotonic solution with 10 mg / ml PVP 17 PF observed a degree of hemolysis of only 17%.
- Another embodiment of the invention relates to the improvement in tolerance by incorporating the active ingredient into mixed micelles consisting of a phospholipid and a bile salt.
- a soy lecithin with a high proportion of phosphatidylcholine can be used as the phospholipid.
- suitable bile salts are cholic acid, glyco-cholic acid and their sodium salts.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02767465A EP1427419A1 (de) | 2001-09-07 | 2002-09-02 | Verbesserung der lokalen verträglichkeit bei intravenöser verabriechung von 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluormethyl-benzoylguanidin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10144030.8 | 2001-09-07 | ||
DE2001144030 DE10144030A1 (de) | 2001-09-07 | 2001-09-07 | Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003022281A1 true WO2003022281A1 (de) | 2003-03-20 |
Family
ID=7698144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/009768 WO2003022281A1 (de) | 2001-09-07 | 2002-09-02 | Verbesserung der lokalen verträglichkeit bei intravenöser verabriechung von 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluormethyl-benzoylguanidin |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1427419A1 (de) |
DE (1) | DE10144030A1 (de) |
WO (1) | WO2003022281A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110339174A (zh) * | 2019-07-09 | 2019-10-18 | 江苏康缘药业股份有限公司 | 一种银杏内酯滴丸及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996019970A1 (en) * | 1994-12-23 | 1996-07-04 | Merck Sharp & Dohme Limited | Hemolysis prevention by surfactants and emulsions |
WO1999010008A1 (en) * | 1997-08-29 | 1999-03-04 | Aquila Biopharmaceuticals, Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
WO2000017176A2 (de) * | 1998-09-22 | 2000-03-30 | Boehringer Ingelheim Pharma Kg | Benzolylguanidin-abkömmlinge mit vorteilhaften eigenschaften, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von arzneimiteln |
WO2002064563A1 (de) * | 2001-02-15 | 2002-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues benzoylguanidinsalz |
-
2001
- 2001-09-07 DE DE2001144030 patent/DE10144030A1/de not_active Withdrawn
-
2002
- 2002-09-02 EP EP02767465A patent/EP1427419A1/de not_active Withdrawn
- 2002-09-02 WO PCT/EP2002/009768 patent/WO2003022281A1/de not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996019970A1 (en) * | 1994-12-23 | 1996-07-04 | Merck Sharp & Dohme Limited | Hemolysis prevention by surfactants and emulsions |
WO1999010008A1 (en) * | 1997-08-29 | 1999-03-04 | Aquila Biopharmaceuticals, Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
WO2000017176A2 (de) * | 1998-09-22 | 2000-03-30 | Boehringer Ingelheim Pharma Kg | Benzolylguanidin-abkömmlinge mit vorteilhaften eigenschaften, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von arzneimiteln |
WO2002064563A1 (de) * | 2001-02-15 | 2002-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues benzoylguanidinsalz |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110339174A (zh) * | 2019-07-09 | 2019-10-18 | 江苏康缘药业股份有限公司 | 一种银杏内酯滴丸及其制备方法 |
CN110339174B (zh) * | 2019-07-09 | 2020-12-11 | 江苏康缘药业股份有限公司 | 一种银杏内酯滴丸及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1427419A1 (de) | 2004-06-16 |
DE10144030A1 (de) | 2003-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3503279C2 (de) | ||
DE3875931T2 (de) | Verbesserung des eindringens in die haut durch verwendung von mischungen der freien base mit dem sauren additionssalz von wirkstoffen. | |
DE69218241T2 (de) | Arzneistofformulierung zur parenteralen anwendung | |
DE60117615T2 (de) | Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen | |
DE69926843T2 (de) | Aktives vitamin-d3 enthaltende lotionen in form von emulsionen | |
EP0265848B1 (de) | Arzneizubereitungen zur oralen Verabreichung, die als Einzeldosis 10 bis 240 mg Dihydropyridin enthalten | |
EP0117888B2 (de) | Flüssigzubereitungen von Dihydropyridinen, ein Verfahren zu ihrer Herstellung, sowie ihre Verwendung bei der Bekämpfung von Erkrankungen | |
DE68907312T2 (de) | Bunazosin oder seine Salze enthaltende pharmazeutische Zubereitungen zur perkutanen Verabreichung. | |
US20060035862A1 (en) | Tolerance of 4-(4-(2-pyrrolycarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration | |
DE69027213T2 (de) | Wasser und Deprodone Proprionate enthaltende Zubereitungen zur äusserlichen Anwendung | |
DE3212736A1 (de) | Verwendung von dihydropyridinen in arzneimitteln mit salidiuretischer wirkung | |
DE60117467T2 (de) | Famotidin-injektionen | |
EP1901732A2 (de) | Verwendung von aktivatoren der löslichen guanylatzyklase zur förderung der wundheilung | |
EP0885613A1 (de) | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin | |
DE69920468T2 (de) | Stabilisierte carvedilol-injektionslösung | |
DE69835167T2 (de) | 1,2,4-benzotriazin-oxide enthaltende zubereitungen | |
DE69001734T2 (de) | Aeusserlich anzuwendende amusulosin enthaltende arzneizubereitung. | |
WO1998041226A9 (de) | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate | |
CH647677A5 (de) | 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung. | |
WO2003022281A1 (de) | Verbesserung der lokalen verträglichkeit bei intravenöser verabriechung von 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluormethyl-benzoylguanidin | |
DE2529149A1 (de) | Topisch anwendbare mittel gegen akne vulgaris | |
EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
DE69636837T2 (de) | 1,2,4-benzotriazinoxid-formulierungen | |
EP2142169B1 (de) | Wässrige pharmazeutische zubereitung | |
DE2401446A1 (de) | Pharmazeutische zubereitungen zur linderung von hautproliferationserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002767465 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002767465 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002767465 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |